Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Weaving single photon imaging into new drug development.

P David Mozley1

  • 1Lilly Corporate Center, Eli Lilly & Company, Indianapolis, IN 46285, USA. moz@lilly.com

Molecular Imaging and Biology
|May 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET.

Nuclear medicine communications·2024
Same author

Reduction in Constitutively Activated Auditory Brainstem Microglia in Aging and Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2024
Same author

[1-<sup>11</sup>C]-Butanol Positron Emission Tomography reveals an impaired brain to nasal turbinates pathway in aging amyloid positive subjects.

Fluids and barriers of the CNS·2024
Same author

The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
Same author

Positron Emission Tomography reveals age-associated hypothalamic microglial activation in women.

Scientific reports·2022
Same author

Decreased CSF clearance and increased brain amyloid in Alzheimer's disease.

Fluids and barriers of the CNS·2022

Single photon emitting radiopharmaceuticals can aid drug development by quantifying pharmacokinetics and visualizing drug action. While direct evidence is limited, potential benefits in oncology and inflammation justify their use.

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical technology
  • Drug development

Background:

  • Single photon emitting radiopharmaceuticals offer potential applications in drug development.
  • Existing literature lacks direct reports on their use in managing drug development programs.

Purpose of the Study:

  • To assess the potential contribution of single photon emitting radiopharmaceutical technologies to new drug development.
  • To identify specific phases and applications where these technologies can add value.

Main Methods:

  • A comprehensive literature search was conducted for studies demonstrating the value of single photon emitters in drug development.
  • Analysis focused on applications such as pharmacokinetics, mechanism of action visualization, safety index estimation, and pharmacodynamic effects.

Related Experiment Videos

  • Extrapolation from feasibility studies was used where direct evidence was absent.

    • Main Results:

    • No published reports were found detailing the use of nuclear medicine techniques in managing drug development progress.
    • Strongest evidence for potential value lies in drug candidates targeting cell proliferation or death, particularly in oncology, cardiology, nephrology, and inflammation.
    • Receptor occupancy studies showed occasional advantages over positron emission tomography (PET).

    Conclusions:

    • Single photon imaging integration into drug development is supported by extrapolations and feasibility studies.
    • Sufficient data exists to justify the cost of single photon imaging in various drug development paradigms.
    • The technology shows particular promise for diseases involving cell proliferation or death.